307 related articles for article (PubMed ID: 28061504)
1. DUB3 Deubiquitylating Enzymes Regulate Hippo Pathway Activity by Regulating the Stability of ITCH, LATS and AMOT Proteins.
Nguyen HT; Kugler JM; Cohen SM
PLoS One; 2017; 12(1):e0169587. PubMed ID: 28061504
[TBL] [Abstract][Full Text] [Related]
2. USP21 regulates Hippo pathway activity by mediating MARK protein turnover.
Nguyen HT; Kugler JM; Loya AC; Cohen SM
Oncotarget; 2017 Sep; 8(38):64095-64105. PubMed ID: 28969054
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability.
Kim Y; Kim W; Song Y; Kim JR; Cho K; Moon H; Ro SW; Seo E; Ryu YM; Myung SJ; Jho EH
Proc Natl Acad Sci U S A; 2017 May; 114(18):4691-4696. PubMed ID: 28416659
[TBL] [Abstract][Full Text] [Related]
5. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
[TBL] [Abstract][Full Text] [Related]
6. The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation.
Wang C; An J; Zhang P; Xu C; Gao K; Wu D; Wang D; Yu H; Liu JO; Yu L
Biochem J; 2012 Jun; 444(2):279-89. PubMed ID: 22385262
[TBL] [Abstract][Full Text] [Related]
7. Amot130 adapts atrophin-1 interacting protein 4 to inhibit yes-associated protein signaling and cell growth.
Adler JJ; Heller BL; Bringman LR; Ranahan WP; Cocklin RR; Goebl MG; Oh M; Lim HS; Ingham RJ; Wells CD
J Biol Chem; 2013 May; 288(21):15181-93. PubMed ID: 23564455
[TBL] [Abstract][Full Text] [Related]
8. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer.
Kim Y; Jho EH
BMB Rep; 2017 Jun; 50(6):281-282. PubMed ID: 28502290
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover.
Thanh Nguyen H; Andrejeva D; Gupta R; Choudhary C; Hong X; Eichhorn PJ; Loya AC; Cohen SM
Cell Discov; 2016; 2():16001. PubMed ID: 27462448
[TBL] [Abstract][Full Text] [Related]
11. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation.
Chan SW; Lim CJ; Guo F; Tan I; Leung T; Hong W
J Biol Chem; 2013 Dec; 288(52):37296-307. PubMed ID: 24225952
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity.
Salah Z; Melino G; Aqeilan RI
Cancer Res; 2011 Mar; 71(5):2010-20. PubMed ID: 21212414
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the Hippo signaling pathway by ubiquitin modification.
Kim Y; Jho EH
BMB Rep; 2018 Mar; 51(3):143-150. PubMed ID: 29366444
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
15. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
16. Hippo signaling is intrinsically regulated during cell cycle progression by APC/C
Kim W; Cho YS; Wang X; Park O; Ma X; Kim H; Gan W; Jho EH; Cha B; Jeung YJ; Zhang L; Gao B; Wei W; Jiang J; Chung KS; Yang Y
Proc Natl Acad Sci U S A; 2019 May; 116(19):9423-9432. PubMed ID: 31000600
[TBL] [Abstract][Full Text] [Related]
17. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
Wang W; Li N; Li X; Tran MK; Han X; Chen J
Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
[TBL] [Abstract][Full Text] [Related]
19. [Role of Hippo-YAP/TAZ signaling pathway in mechanotransduction.].
Ishihara E; Nishina H
Clin Calcium; 2016; 26(12):1751-1756. PubMed ID: 27885187
[TBL] [Abstract][Full Text] [Related]
20. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.
Lim SK; Lu SY; Kang SA; Tan HJ; Li Z; Adrian Wee ZN; Guan JS; Reddy Chichili VP; Sivaraman J; Putti T; Thike AA; Tan PH; Sudol M; Virshup DM; Chan SW; Hong W; Lim YP
Cancer Res; 2016 Nov; 76(21):6278-6289. PubMed ID: 27578003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
